Search Results | Blood | American Society of Hematology

1-20 of 168

Sort by

Sort Order Select

Journal Articles

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

Blood (2023) 141 (6): 579–591.

DOI: https://doi.org/10.1182/blood.2022016782

Published: 2023

Includes: Supplemental data

Journal Articles

Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification

Blood (2022) 140 (Supplement 1): 1566–1567.

DOI: https://doi.org/10.1182/blood-2022-170249

Published: 2022

Journal Articles

Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination

Blood (2022) 140 (Supplement 1): 1957–1959.

DOI: https://doi.org/10.1182/blood-2022-169164

Published: 2022

Journal Articles

Modakafusp Alfa (TAK-573), a Novel CD38-Targeting Attenuated Interferon-Alpha Immunocytokine, Kills MM Cells Via NK Cell Activation

Wassilis S.C. Bruins, Rosa Rentenaar, Sabrina Collins, James F. Sampson, Niels WCJ Van De Donk, Sonja Zweegman, Tuna Mutis

Blood (2022) 140 (Supplement 1): 4236–4237.

DOI: https://doi.org/10.1182/blood-2022-156387

Published: 2022

Journal Articles

High Immunoproteasome Expression As Indicator for Sensitivity to Bortezomib-Containing Chemotherapy in Newly Diagnosed, Standard and Intermediate Risk, T-Cell Acute Lymphoblastic Leukemia Patients from Children's Oncology Group Trial AALL1231

Margot S.F. Roeten, Johan van Meerloo, Zinia Kwidama, Gaye Jenkins, Suzanne N. van Dijk, David T. Teachey, Meenakshi Devidas, Mignon L. Loh, Gertjan J.L. Kaspers, Sonja Zweegman, Gerrit Jansen, Jacqueline Cloos, Terzah M. Horton

Blood (2022) 140 (Supplement 1): 9183–9184.

DOI: https://doi.org/10.1182/blood-2022-162412

Published: 2022

Journal Articles

Preclinical Activity of Allogeneic CS1-Specific CAR T-Cells (UCARTCS1) in Multiple Myeloma

Charlotte L.B.M. Korst, Wassilis S.C. Bruins, Meliha Cosovic, Christie P.M. Verkleij, Inoka Twickler, Diane Le Clerre, Isabelle Chion-Sotinel, Sonja Zweegman, Roman Galetto, Tuna Mutis, Niels WCJ Van De Donk

Blood (2022) 140 (Supplement 1): 4215–4216.

DOI: https://doi.org/10.1182/blood-2022-157950

Published: 2022

Journal Articles

Single-Cell Transcriptomic Analysis Reveals Reduction of Cytotoxic NK Cells in a Subset of Newly Diagnosed Multiple Myeloma Patients Impacting Outcome after Daratumumab Therapy

Sabrin Tahri, Madelon M.E. de Jong, Cathelijne Fokkema, Natalie Papazian, Zoltan Kellermayer, Michael Vermeulen, Mark van Duin, Pieter van de Woestijne, Kazem Nasserinejad, Elona Saraci, Mattia D'Agostino, Francesca Gay, Vincent H.J. van der Velden, Niels WCJ Van De Donk, Annemiek Broijl, Pieter Sonneveld, Sonja Zweegman, Tom Cupedo

Blood (2022) 140 (Supplement 1): 9982–9984.

DOI: https://doi.org/10.1182/blood-2022-164812

Published: 2022

Journal Articles

Comparison of Hidac Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Study

Man Wai Tang, Deborah van der Tuin, Mesire Aydin, Jarom Heijmans, Arjan A. van de Loosdrecht, Ellen Meijer, Caroline E. Rutten, Marielle Wondergem, Jeroen J.W.M. Janssen, Marjolein Donker, Mette D. Hazenberg, Sonja Zweegman, Bart J. Biemond, David C. de Leeuw, Erfan Nur

Blood (2022) 140 (Supplement 1): 3287–3289.

DOI: https://doi.org/10.1182/blood-2022-163042

Published: 2022

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Blood (2022) 140 (Supplement 1): 4420–4422.

DOI: https://doi.org/10.1182/blood-2022-165942

Published: 2022

Journal Articles

Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies

Blood (2022) 140 (Supplement 1): 8347–8349.

DOI: https://doi.org/10.1182/blood-2022-168991

Published: 2022

Journal Articles

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

Blood (2022) 140 (Supplement 1): 7536–7537.

DOI: https://doi.org/10.1182/blood-2022-159169

Published: 2022

Journal Articles

Cost-effectiveness: maximizing impact by meticulous data

Hedwig M. Blommestein, Sonja Zweegman

Blood (2022) 140 (6): 525–526.

DOI: https://doi.org/10.1182/blood.2022016958

Published: 2022

Journal Articles

CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy

Blood (2021) 138 (Supplement 1): 2910.

DOI: https://doi.org/10.1182/blood-2021-146074

Published: 2021

Journal Articles

For Better or for Worse: COVID-19 Vaccination during or Early after (Immuno-) Chemotherapy or Hematopoietic Progenitor Cell Transplantation

Sabine Haggenburg, Birgit I. Lissenberg-Witte, Robert S. Van Binnendijk, Gerco Den Hartog, Bhoekhan S. Michel, Nienke J.E. Haverkate, Dennis M. De Rooij, Annoek E.C. Broers, Pim G.N.J. Mutsaers, Tom Van Meerten, Jaap van Doesum, Arnon P. Kater, Sonja Zweegman, Marit J. Van Gils, Bram Goorhuis, Caroline E. Rutten, Mette D. Hazenberg, Inger S. Nijhof

Blood (2021) 138 (Supplement 1): 754.

DOI: https://doi.org/10.1182/blood-2021-150379

Published: 2021

Journal Articles

Immune Profiling of Multiple Myeloma Patients Treated with Daratumumab Monotherapy: Acquired and Primary Daratumumab-Resistance Is Associated with NK Cell Exhaustion

Blood (2021) 138 (Supplement 1): 728.

DOI: https://doi.org/10.1182/blood-2021-150913

Published: 2021

Journal Articles

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Blood (2021) 138 (Supplement 1): 80.

DOI: https://doi.org/10.1182/blood-2021-152112

Published: 2021

Journal Articles

Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

Blood (2021) 138 (Supplement 1): 82.

DOI: https://doi.org/10.1182/blood-2021-147897

Published: 2021

Journal Articles

High-Dose Melphalan in 1 Day Versus over 2 Days Followed By Autologous Stem Cell Transplantation As Consolidation Treatment in Patients with Multiple Myeloma

Mesire Aydin, Man Wai Tang, Marielle Wondergem, David C. de Leeuw, Jurgen J. Wegman, Bart J. Biemond, Niels W.C.J. van de Donk, Sonja Zweegman, Ellen Meijer, Erfan Nur

Blood (2021) 138 (Supplement 1): 3944.

DOI: https://doi.org/10.1182/blood-2021-147860

Published: 2021

Journal Articles

Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network

Blood (2021) 138 (Supplement 1): 3792.

DOI: https://doi.org/10.1182/blood-2021-145289

Published: 2021

Journal Articles

Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with First Progression of Multiple Myeloma Refractory to Bortezomib and Lenalidomide. Final Report of the EMN011/HOVON114 Trial

Pieter Sonneveld, Sonja Zweegman, Michele Cavo, Kazem Nasserinejad, Annemiek Broyl, Rosella Troia, Ludek Pour, Sandra Croockewit, Paolo Corradini, Gerard M.J. Bos, Ka Lung Wu, Jolanda Droogendijk, Monique C. Minnema, Mario Boccadoro

Blood (2021) 138 (Supplement 1): 1664.

DOI: https://doi.org/10.1182/blood-2021-149423

Published: 2021

NARROW

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification

Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination

Modakafusp Alfa (TAK-573), a Novel CD38-Targeting Attenuated Interferon-Alpha Immunocytokine, Kills MM Cells Via NK Cell Activation

High Immunoproteasome Expression As Indicator for Sensitivity to Bortezomib-Containing Chemotherapy in Newly Diagnosed, Standard and Intermediate Risk, T-Cell Acute Lymphoblastic Leukemia Patients from Children's Oncology Group Trial AALL1231

Preclinical Activity of Allogeneic CS1-Specific CAR T-Cells (UCARTCS1) in Multiple Myeloma

Single-Cell Transcriptomic Analysis Reveals Reduction of Cytotoxic NK Cells in a Subset of Newly Diagnosed Multiple Myeloma Patients Impacting Outcome after Daratumumab Therapy

Comparison of Hidac Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Study

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

Cost-effectiveness: maximizing impact by meticulous data

CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy

For Better or for Worse: COVID-19 Vaccination during or Early after (Immuno-) Chemotherapy or Hematopoietic Progenitor Cell Transplantation

Immune Profiling of Multiple Myeloma Patients Treated with Daratumumab Monotherapy: Acquired and Primary Daratumumab-Resistance Is Associated with NK Cell Exhaustion

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

High-Dose Melphalan in 1 Day Versus over 2 Days Followed By Autologous Stem Cell Transplantation As Consolidation Treatment in Patients with Multiple Myeloma

Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with First Progression of Multiple Myeloma Refractory to Bortezomib and Lenalidomide. Final Report of the EMN011/HOVON114 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only